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Background: Community pharmacies may offer an accessible way of delivering weight-management programmes
but there have been few trials that use clinically significant weight loss outcomes, objective measures of weight
and follow-up to 12 months. We aimed to evaluate weight change among patients who used the Counterweight
weight management programme delivered by community pharmacies.
Methods: The Counterweight Programme was introduced into community pharmacies in Fife, Scotland in 2009 for
patients with a BMI ≥ 30 kg/m2 or a BMI ≥ 2
not available at GP practices. The aim was to achieve an energy deficit of 500-600 kcal per day. Counterweight
specialist dietitians delivered training, support and patient information materials to community pharmacies. Patient
weight was measured by pharmacy staff at each weight management session. Weight data recorded at each
weight management session were used to estimate weight change and attendance at 3, 6 and 12 months.
Results: Between March 2009 and July 2012, 458 patients were enrolled by the community pharmacies. Three-quarters
of patients were women, mean age was 54 (SD 7.4) years and mean BMI 36.1 (SD 5.9) kg/m2. Of 314 patients enrolled
for at least 12 months, 32 (10.2% on an intention to treat basis) had achieved the target weight loss of ≥5%; this was
41.6% of those who attended at 12 months representing a mean weight loss of 4.1 kg. Using Last Observation Carried
Forward, 15.9% achieved the target weight loss within 12 months of enrolling. There was no significant effect of sex,
baseline BMI or age on weight loss.
Conclusions: The Counterweight pharmacy programme has a similar effectiveness to other primary care based weight
management programmes and should be considered as part of a range of services available to a community to
manage overweight and obesity.
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28 kg/m with a co-morbidity in localities in which Counterweight wasBackground
Obesity is an important risk factor for many chronic
conditions, such as cardiovascular diseases, cancers and
diabetes mellitus [1-3]. The worldwide prevalence of
obesity has doubled since 1980 [4]. In the UK it has tre-
bled in the past thirty years and further increases are
predicted [5,6]. A range of approaches will be needed to
halt the increase in obesity and to reduce its prevalence.
These will include primary prevention by engineering
public places to promote physical activity and encour-
aging the avoidance of unhealthy foods [7]. Effective* Correspondence: philip.mcloone@glasgow.ac.uk
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reproduction in any medium, provided the ortreatment of overweight and established obesity, how-
ever, will also be needed [8]. Several models for provid-
ing obesity management in primary care have been
reported, including the use of community pharmacies.
It is estimated that 95% of the population visit a com-
munity pharmacy during the year [9,10]. Because of this,
pharmacies in Scotland have been encouraged to provide
a variety of health related services - these have included
health assessments for diabetes, cardiovascular diseases,
asthma, and smoking cessation [9]. Pharmacies also offer
over-the-counter weight loss products [11]. Where phar-
macy has been used as one treatment arm in a
randomised controlled trial comparing a range of weight
reduction programmes, 14% of pharmacy participants
lost at least 5% of their initial weight although there wasal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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months [12]. A recent systematic review of the effective-
ness and cost effectiveness of community pharmacy-based
weight management identified 10 initiatives involving 582
pharmacies in 5 countries. The authors of the review
found that community pharmacy weight management
could produce modest weight loss at 12 months of be-
tween 1.1-4.1 kg, but concluded that there was insufficient
evidence of effectiveness and cost effectiveness because of
limitations in how the studies were carried out and
reported [13]. For example, only 3 studies reported long-
term (12 month) weight change; only one study employed
evidence-based guidelines in its programme; and few
reported any cost information. The authors of the review
recommended that body weight should be objectively
measured and that proportions of patients achieving clin-
ically significant weight loss should be reported alongside
mean weight loss to enable comparison of effectiveness
from a clinical point of view [13]. The health benefits of
clinically significant weight loss, defined as loss of ≥5%
baseline weight, include reduced blood pressure, improved
glycaemic control, reduction in risk of type 2 diabetes, im-
proved lipid profiles, and reduced osteoarthritis-related
disability [14].
Counterweight is a weight management programme
that has been evaluated for use in routine National
Health Service primary care [15,16]. A case series study
showed that it achieved clinically significant long-term
weight loss in 14% of all patients at 12 months [16]. The
programme was introduced into community pharmacies
in the Fife region of Scotland in 2009. Our aim was
to evaluate the effectiveness of the Counterweight
Programme delivered within community pharmacies,
using a primary outcome of clinically significant
weight change at 12 months.Methods
Counterweight intervention
The Counterweight weight management programme
was provided in the Fife region (population 365,000) as
part of the Keep Well project. The Keep Well project
encourages 40 to 64 year olds, who live in geographical
areas which have been identified as having greatest need,
to improve their health. The program targets those indi-
viduals at high risk of cardiovascular disease, and offers
medical advice and support through enhanced Primary
Care services. Between 2008 and 2010, 50 general prac-
tices in Fife were engaged in the delivery of the Keep
Well project. Patients registered with participating prac-
tices who had a BMI ≥ 30 kg/m2 or a BMI ≥ 28 kg/m2
with a co-morbidity and who were assessed as being mo-
tivated to lose weight were referred to the Counter-
weight Programme.Eighty community pharmacies were approached to
determine interest in delivering the Counterweight
Programme. Twenty three pharmacies expressed an
interest, and 18 were invited because they were located
in geographical areas where local general practices did
not deliver Counterweight. Sixteen pharmacies subse-
quently agreed to deliver the programme and received
training. Twelve of the participating pharmacies where
situated in small urban settlements [17] with between
10,000 to 125,000 inhabitants. The remaining four were
located in small towns of 3,000–10,000 people. Partici-
pating pharmacies were required to have a private con-
sultation room and time to deliver the intervention. All
pharmacies had extended opening hours and offered ap-
pointments in the evening and at weekends. Marsden
High Capacity Portable Scales (Class III) and Seca
Leicester Portable Height Measures were supplied by the
NHS Fife Keep Well project to measure weight and
height. Scales were calibrated on an annual basis [18].
Counterweight resources (training manuals, desk top flip
charts and patient information booklets) were initially
funded through the core Counterweight Scottish
Government funding. Pharmacies were paid a single
commitment fee of £100 for taking part, plus a payment
per patient and payments for the provision of replace-
ment staff while staff were trained . Between March
2009 and May 2010, the payment per patient was £54,
which comprised £30 for patients attending 1-3 appoint-
ments and a further £24 for patients attending 4 or more
appointments. From May 2010 to date these payments
rose to £64 and £40, respectively.
Specialist dietitians competent in Counterweight
Programme delivery conducted two four-hour training
sessions and a further 3 hour session after 6 months to
consolidate the initial training. Most trained staff were
pharmacy assistants rather than pharmacists. It was agreed
that pharmacy staff would not sell over-the-counter weight
loss medications to patients enrolled in the programme.
The specialist dietitians also provided mentoring to
all pharmacies.
The Counterweight approach to weight management
has been described in detail elsewhere [16]. In brief,
pharmacy staff delivered patient education by discussing
weight management, and communicating information
on behaviour change strategies. The initial interventions
involved a prescribed eating plan or a goal-setting
approach. The aim was to achieve an energy deficit of
500-600 kcal/day. As patients progressed through the
programme, emphasis was increasingly directed to
weight loss maintenance and the prevention of weight
regain. Patients were asked to commit to nine appoint-
ments in 12 months following the initial screening visit.
This included six initial appointments (10–30 minutes
each) with follow-up visits at 6, 9 and 12 months. The
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programme was estimated at 130 minutes.
The data collected at each visit were recorded using
paper based patient forms. Anonymised patient forms
were collated centrally and entered into a bespoke
Microsoft Access database. The data were checked for
incomplete or inaccurate information. The central data-
base was sent to an independent team at Glasgow
University at set time points.
Ethics
Formal ethical approval was unnecessary as this was
an audit of a planned delivery of an existing interven-
tion, no new or untested treatment was being offered,
and there was no experimentation. No personally
identifiable data were collected and written consent was
not required.
Data definitions
Baseline weight and height were collected when patients
attended the first session of the weight loss programme.
During the first appointment patients were asked
whether they smoked and whether they had diabetes.
Their response was recorded as a binary variable (yes/
no). Smoking and diabetes status were recorded because
they are relevant factors associated with weight, attend-
ance and weight loss. Weight was measured at each sub-
sequent visit. Weight change was evaluated at 3, 6 and
12 months. The weight measurements used in the evalu-
ation were recorded in kilograms at dates closest to 3, 6
and 12 calendar months from enrolment (within time
frames of 6–15 weeks, 15 weeks–9 months, and 9 – 18 -
months respectively). The primary outcome of the study
was weight loss of at least 5% of baseline weight at
12 months.
Statistical methods
Descriptive statistical methods were used to present
change in weight at 3, 6 and 12 months. Values are
presented as means and 95% confidence intervals (95%
CI), if not indicated otherwise. We present weight
change as absolute weight change and the percentage
achieving at least 5% weight loss. The analyses were car-
ried out separately for patients who attended at each
time point, and for all patients assuming that partici-
pants for whom weight at follow-up was not available
retained their baseline weight (baseline-observation-
carried-forward BOCF), and assuming participants
retained their last observed weight (last-observation-
carried-forward LOCF). BOCF and LOCF were included
to enable comparison with other studies, but they are
biased methods of imputing missing data [19].
Kruskal-Wallis one way analysis of variance, the chi-
square test for differences in proportions and logisticregression were used to examine the association of age,
sex, and starting BMI with weight loss and attendance.
Age and BMI were employed both as continuous and
categorical variables. Age was categorised into 3 groups
(<50, 50-59, and 60+ years). BMI was categorised as fol-
lows <30, 30- < 35, 35- < 40, and 40+ kg/m2. The con-
ventional statistical significance threshold of 5% was
used (p < 0.05). All analyses were conducted with STATA
version 11 (StataCorp, CollegeStation, TX, USA).
Results
Between March 2009 and July 2012, 458 patients were
enrolled by 16 community pharmacies. The baseline
characteristics of patients are shown in Table 1. Sex, age
and BMI were not recorded for 2 (0.4%), 12 (2.6%) and 6
(1.3%) patients respectively. Three-quarters of patients
were women, mean age was 54 years and mean BMI was
36.0 kg/m2. One-fifth of patients had a BMI of 40 kg/m2
or over. Smoking was reported among 14% of patients.
Patients who smoked had a slightly lower mean BMI
34.3 kg/m2 (95% CI 33.0, 35.6) than those who reported
that they did not smoke 36.6 kg/m2 (35.9, 37.3) (p =
0.005). One in ten patients reported diabetes. Patients
with diabetes had a higher baseline BMI 39.1 kg/m2
(37.0, 41.2) than patients who did not have diabetes
35.8 kg/m2 (35.2, 36.4) (p = 0.002).
Attendance and weight change at 3, 6 and 12 months
are shown in Table 2. Of the 458 patients who started
Counterweight within the enrolment period, progres-
sively fewer had been in the programme long enough to
be eligible to attend at later time points. Attendance
declined over time from 56.0% at 3 months to 24.5% at
12 months. Of 314 patients enrolled for at least 12 -
months, 32 (10.2%) had achieved the target weight loss
of ≥5%. This represents 41.6% of those who attended at
12 months.
The distribution of weight change at 3, 6 and 12 -
months is illustrated in Figure 1. Weight change was ap-
proximately symmetrically distributed around the mean
at 3 and 6 months. At 12 months there was stronger evi-
dence of skew in the distribution; for example 2 patients
lost more than 20 kgs. There were progressively larger
mean weight losses over time, from 2.4 kg at 3 months
to 4.1 kg at 12 months. At 12 months, 57 patients (74%
of patients who attended, 18% of all patients) had lost
some weight, 15 patients (19% of patients who attended,
5% of all patients) had gained weight and 5 (6% of
patients who attended, 2% of all patients) had no appre-
ciable change in weight since baseline (absolute change ≤
250 g). The maximum weight loss was 27 kg and the
maximum weight gain 4.6 kg at 12 months. Weight
change, expressed as a percentage of baseline weight,
was similar to absolute weight change because the mean
baseline weight was close to 100 kg (data not shown).
Table 1 Baseline characteristics of 458 Counterweight patients enrolled in community pharmacies
Patients (n = 458)
Baseline characteristics % or mean (n or SD)
Men% 24.9 (114)
Women% 74.7 (342)
Age mean years (SD) 54.0 (7.4)
Weight mean kg (SD) 96.4 (18.3)
Starting BMI mean kg/m2 (SD) 36.0 (5.9)




not recorded 1.3 (6)
Smoking status% smoker 14.4 (66)
not recorded 18.8 (86)
Diabetes Status% diabetic 11.6 (53)
not recorded 15.7 (72)
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12 months (Table 3). Attendance increased with age and
decreased with increasing BMI but these trends were
not statistically significant. Men appeared to lose more
weight than women (5.8 kg vs. 3.4 kg; p = 0.66 - Table 3)
but there was no difference in clinically significant
weight loss (39% vs. 43%; p = 0.78). A relationship be-
tween weight loss and age or BMI was not apparent.
Table 3 shows that patients aged 40-49 lost more weight
than other age groups while those with a BMI 30-34 kg/m2
lost the least amount of weight. Statistically significant
differences were not found when weight loss was
modelled by sex, age and BMI individually (sex p = 0.66;
age p = 0.66; BMI p = 0.21 - Table 3) or in combination.
The percentage achieving ≥5% weight loss similarly did
not show statistically significant associations with sexTable 2 Weight loss among patients at 3, 6, and 12 months s
3 months n =
% or mean (n or
Attendance% (n) 56.0 (241)
Weight loss mean kg (95% CI*) Attending patients 2.4 (2.02, 2.70)
BOCF** 1.3 (1.10, 1.54)
LOCF*** 1.3 (1.10, 1.54)
≥5% weight loss% (95% CI*) Attending patients 17.0 (12.5, 22.4)
BOCF** 9.5 (6.9, 12.7)
LOCF*** 9.5 (6.9, 12.7)
*95% confidence interval.
**BOFC - baseline observation carried forward.
***LOFC - last observation carried forward.(p = 0.78), age (p = 0.86) or BMI (p = 0.86). Table 3
shows that the imputed measures of mean weight loss
(BOCF and LOCF) produced substantially lower estimates
of mean weight loss than estimates based only on patients
who attended. Both BOCF and LOFC estimates similarly
showed non-significant patterns by age and BMI.
Patients who smoked had similar weight loss as patients
who did not smoke (Table 4). Patients with diabetes who
attended at 12 months appeared to lose less weight
compared to patients without diabetes (1.8 kg vs. 4.6 kg;
p = 0.24 - Table 4), but a difference was not apparent when
the proportions (LOCF) with clinically significant weight
loss were compared (15% vs. 17%; p = 0.78). Patients who
did not report smoking or diabetes status appeared to be
less likely to attend at 12 months (p = 0.07 & p = 0.08
respectively - Table 4).ince starting programme
Time since starting programme
430 6 months n = 395 12 months n = 314
95% CI*) % or mean (n or 95% CI*) % or mean (n or 95% CI*)
33.7 (133) 24.5 (77)
3.5 (2.66, 4.25) 4.1 (2.83, 5.41)
1.2 (0.85, 1.58) 1.0 (0.64, 1.38)
1.6 (1.25, 1.89) 1.7 (1.31, 2.14)
34.6 (26.6, 43.3) 41.6 (30.4, 53.4)
11.6 (8.7, 15.2) 10.2 (7.1, 14.1)
13.9 (10.7, 17.7) 15.9 (12.1, 20.4)
Figure 1 Dot plot comparing weight change at 3, 6, and 12 months since enrollment. Boxes indicate 25th, 50th and 75th percentiles.
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Our study reports on the largest prospective evalu-
ation of a pharmacy based weight management
programme in the UK over a twelve month follow-up
period. We found that 10% of patients enrolled in
a community pharmacy-based weight management
programme had lost ≥5% of baseline weight after













Men 79 29.1 (19.4, 40.4) 5.79 (2.47, 9.10) 1.69 (0.58,
Women 234 23.1 (1.78, 29.0) 3.41 (2.25, 4.57) 0.79 (0.47,
p value 0.28 0.66 0.62
Age group
(years)
40-49 61 19.7 (10.6, 31.8) 4.78 (1.50, 8.06) 0.94 (0.16,
50-59 134 24.6 (17.6, 32.8) 3.50 (1.40, 5.59) 0.86 (0.30,
60+ 111 27.9 (19.8, 37.2) 4.29 (2.36, 6.22) 1.20 (0.56,
p value 0.49 0.66 0.77
BMI grouping
(kg/m2)
<30 30 26.7 (12.3, 45.9) 5.37 (2.35, 8.38) 1.43 (0.24,
30- < 35 136 25.7 (18.6, 33.9) 2.61 (1.35, 3.88) 0.67 (0.30,
35- < 40 80 23.8 (14.9, 34.6) 3.82 (1.09, 6.55) 0.91 (0.17,
40+ 64 23.4 (13.8, 35.7) 7.35 (3.08, 11.63) 1.72 (0.47,
p value 0.97 0.21 0.74
*95% confidence interval. **BOFC - baseline observation carried forward. ***LOFC -maintenance at 12 months requires both initial weight
loss and continued attendance and we found that
these did not differ significantly by age, sex or baseline
BMI. Attendance was highest among men, and appeared
to increase with age and decrease with increasing BMI.
Weight loss – measurable only among attendees – was
greatest in men and patients under 50 but showed no
clear relationship to BMI.weight loss at 12 months by sex, age and Body Mass
ight loss (kg) Percentage (95% CI*) of patients




2.79) 2.53 (1.41, 3.56) 39.1 (19.7, 61.5) 9.8 (6.3, 14.4) 17.7 (10.0, 27.9)
1.11) 1.46 (1.05, 1.86) 42.6 (29.2, 56.8) 11.4 (5.3, 20.5) 15.4 (11.0, 20.7)
0.21 0.78 0.69 0.62
1.72) 1.49 (0.56, 2.43) 50.0 (21.1, 78.9) 9.8 (3.7, 20.2) 16.4 (8.2, 28.1)
1.43) 1.66 (1.01, 2.32) 39.4 (22.9, 57.9) 9.7 (5.3, 16.0) 15.7 (10.0, 23.0)
1.84) 1.91 (1.22, 2.61) 38.7 (21.8, 57.8) 10.8 (5.7, 18.1) 16.2 (9.9, 24.4)
0.57 0.78 0.96 0.99
2.63) 2.02 (0.78, 3.25) 75.0 (34.9, 96.8) 20.0 (7.7, 38.6) 23.3 (9.9, 42.3)
1.05) 1.40 (0.89, 1.91) 37.1 (21.5, 55.1) 9.6 (5.2, 15.8) 16.2 (10.4, 23.5)
1.64) 1.66 (0.84, 2.48) 31.6 (12.6, 56.6) 7.5 (2.8, 15.6) 13.8 (7.1, 23.3)
2.98) 2.39 (1.08, 3.70) 46.7 (21.3, 73.4) 10.9 (4.5, 21.2) 15.6 (7.8, 26.9)
0.91 0.18 0.28 0.68
last observation carried forward.






Mean 12 month weight
loss (kg) (95% CI*)
% losing 5% weight
(BOCF**) (95% CI*)
% losing 5% weight
(LOCF***) (95% CI*)
Smoking status smokers 45 28.9 4.47 (0.60, 8.35) 11 (4, 24) 13 (5, 27)
non smokers 210 26.2 4.19 (2.60, 5.79) 11 (7, 16) 17 (12, 22)
not recorded 59 15.3 3.16 (0.69, 5.63) 7 (2, 16) 15 (7, 27)
p value 0.17 0.99 0.63 0.85
Diabetes status diabetes 33 21.2 1.78 (-0.80, 4.34) 3 (0, 16) 15 (5, 32)
no diabetes 228 27.2 4.57 (3.02, 6.13) 12 (8, 17) 17 (12, 23)
not recorded 53 15.1 2.66 (0.12, 5.12) 6 (1, 16) 11 (4, 23)
p value 0.16 0.36 0.13 0.58
*95% confidence interval.
**BOCF - baseline observation carried forward.
***LOFC - last observation carried forward.
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reported mean weight losses of 1.19 kg (95% CI -0.7 to
3.1), corresponding to 14.3% of the cohort (using BOCF)
losing ≥5% at one year among users of a pharmacy-
based weight management programme [12]. Weight
losses in our pharmacy trial were similar, with mean loss
at 12 months of 1.01 kg (0.64, 1.38) (BOCF) but the
proportion achieving a ≥5% loss was lower, at 10.2%.
Lighten Up pharmacy patients had lower baseline BMIs
than our pharmacy group (96% vs. 78% respectively with
BMI < 40), they were younger (mean age 49 vs. 54 years)
but a similar proportion were men (27% vs. 25%). As we
did not find significant effects of either BMI or age on
weight loss, it seems unlikely that these explain the
observed difference in outcomes. However, 20% of
weights reported in the Lighten Up pharmacy group
were self-reported and weights were available for 57% of
patients, compared to our 25%. It would seem that the
community pharmacies delivering the Counterweight
Programme were poorer at retaining patients but more
effective in achieving clinically meaningful weight losses
among those who attended. Assessment of readiness to
change, for example the stages of change model by
Prochaska [20], is widely used in health promotion inter-
ventions and is part of the Counterweight Programme.
Such information was not collected as part of routine data
recording in our study. Improved screening with regular
review of motivation may improve retention and efficacy
of the programme. Among the three pharmacy studies
identified by Gordon and others that reported 12-month
outcomes [13], one reported mean weight losses of up to
2.4 kg (2.7%) with the addition of high risk counselling
[21]; another reported 1.9 kg mean weight loss [22]; and a
third reported mean weight loss of 4.1 kg [23,24]. Toubro
and others’ study [23], however, used baseline and subse-
quent self-reported weights only, and is possibly affected
by reporting bias.Evidence-based weight loss programmes for adults in
the UK report 12 month mean weight loss ranging from
1.1 to 6.6 kg, and they achieve 5% weight loss for between
14% to 46% of patients [25]. Commercial community-
based organizations such as Weight-Watchers appear to
be more effective [26], but a direct comparisons between
programmes is difficult because of differences in the case-
mix of patients they serve and the context in which the
programmes are delivered. All programmes suffer from
high attrition which limits the ability to compare outcome
data. Effective ways to increase retention and attendance
are needed, and this may improve weight loss outcomes
by increasing the time spent in programme participation.
Weight loss programmes based within community phar-
macies have the attraction of being widely accessible
which may increase participation. Our study, however,
found that when the Counterweight Programme was
based in pharmacies, attendance at 12 months was com-
parable to that achieved when the programme was deliv-
ered in general practice (25% vs. 28%) [27].
Our study has several strengths and weaknesses. Its
strengths are that it reports weight loss using a clinically-
based threshold of ≥5% rather than a mean weight change
in a patient group; weights were objectively measured and
not self-reported; and that it describes long-term weight
loss rather than end-of-programme results. Weaknesses of
the study include possible unrepresentativeness of the pa-
tients or pharmacies and a lack of detailed information
about other social and clinical factors that may have
influenced patients’ attendance and weight loss. The Keep
Well population, for example, is composed of patients
from disadvantaged areas, identified at being at high risk
of ill health, and who are not fully engaged with primary
care services. The present study was not an RCT and we
did not employ a comparison group. It is difficult to re-
cruit (particularly to a control group) and conduct such a
study when pharmacies were the main delivery point of
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the study population was composed mainly of patients
from disadvantaged backgrounds.
In established practice the Counterweight Programme
delivered in primary care achieved ≥5% weight loss at 12 -
months in 10% of patients [27] and this Counterweight
Programme delivered in pharmacies also achieved the
same weight loss in 10% of patients. Our study indicates
the effectiveness of a programme delivered in areas where
GPs would not provide Counterweight services and we
therefore suggest that pharmacy-delivered weight manage-
ment remains an option that should be considered where
alternatives are not available.
Conclusions
In conclusion, we have demonstrated that a pharmacy-
based weight management programme achieves clinically
significant, objectively-measured weight losses at 12 months
in 10% of patients who enrol. There are few other
evaluations of long-term weight loss outcomes in
community pharmacies and several include self-reported
weights, which may be subject to significant reporting
biases. The Counterweight Programme delivered in
pharmacies should be considered as part of a range of
services available to a community to manage overweight
and obesity.
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